Good MorningEquity markets ended the week, month and year on a sour note falling more than 1.0% at the low of the day on Friday to cap off a year of selling in the stock market. The S&P 500 shed more than 25% at the depths of the correction and may reach those levels again in 2023. The risk for the market this year is not only a worsening outlook for corporate earnings but a growing possibility for a deep recession.
This week may be another week of listless trading but the action will heat up soon enough. The calendar Q4 2022 earnings reporting season begins with releases from JPMorgan and other major banks along with key reports from other sectors. As it is, the market is expecting to see S&P 500 earnings fall by roughly 3.0% on average which will be the first decline in earnings since the depths of the pandemic in Q3 of 2020. Featured: The case for trading fewer setups, not more (Ad) 
|
Retail/Wholesale | |
2022 has been challenging for big tech. While the QQQ NASDAQ Index tracking stock (NYSE: QQQ) is down more than 33% from its post-pandemic peak names like Facebook (cough Meta Platforms (NASDAQ: META)), Amazon (NASDAQ: AMZN) and Salesforce.com (NYSE: CRM) are down more than 50%, and the figure may... Read the Full Story |
|
From Our Partners | | Oracle runs 15,000 stocks through the same filter every single day, scanning for precise setups before the opening bell - no emotion, no guesswork.
Tim Bohen, Lead Trainer at StocksToTrade, is walking through this week's flagged setups and showing exactly how the scanner works in a live training right now. | | Watch the scanner in action and join the live training now |
|
Technology | |
Microsoft Corporation (NASDAQ: MSFT) scooped up a 4% stake in the London Stock Exchange Group (LON: LSEG) this month. Investors might wonder what significance this will have for the company moving forward.
As part of the acquisition, the companies will work to create a "centralized, financia... Read the Full Story |
|
Medical | |
At first glance, it might seem like Kintara Therapeutics Inc (Nasdaq: KTRA) would not be a good investment. After all, analysts gave the stock a HOLD rating after its Q3 earnings report in November. However, that rating alone is not enough to understand the full scope of possibility in its future,... Read the Full Story |
|
From Our Partners | | Every morning before the market opens, a scanner called Oracle runs through 15,000 stocks and scores the setups — so there's already a plan in place by 6:15 a.m.
Lead Trainer Tim Bohen of StocksToTrade is walking through exactly how Oracle works and how regular traders are using it in a training running right now. | | Watch the Oracle training now and see how the scanner works |
|
Industrials | |
Power generation and energy storage systems maker Generac Holdings Inc. (NASDAQ: GNRC) stock has been a heartbreaker. Shares were trading at a high of $524.31 just over a year ago before shares fell to a new weekly lower low of $86.29 in late December, falling below its pre-pandemic levels.
With ... Read the Full Story |
|
Technology | |
This article highlights three high-yield dividend stocks that investors will want to consider buying in 2023. Investors are expecting another volatile year. And owning dividend stocks is a time-honored way to stay invested during market volatility.
Because these companies pay shareholders a per... Read the Full Story |
|
From Our Partners | | The U.S. government has taken roughly a 10% stake in Intel, negotiated a 15% cut of Nvidia and AMD chip sales to China, and reportedly received a 5% ownership offer - worth around $40 billion - from the most valuable AI company on earth.
Porter Stansberry calls it the New U.S.A.I. - a state-backed arrangement where Washington and a handful of tech giants are fused at the balance sheet. A small number of companies get pulled inside. Everyone else gets frozen out, including names sitting in your index fund right now. | | Watch the documentary to see which companies are on the right side |
|
Basic Materials | |
Shares of Cal-Maine (NASDAQ: CALM) are moving lower in pre-market action, and it might make you think the company had a bad fiscal 2nd quarter. That is not the truth. The truth is that Cal-Maine had a record-setting quarter on many levels and is in a position to do so again and again in calendar 2... Read the Full Story |
|
Auto/Tires/Trucks | |
Tesla, Inc. (NASDAQ: TSLA) is not bringing much holiday cheer to investors. In a shortened trading week, Tesla is one of MarketBeat's Most Active Stocks by dollar volume. But that volume is significantly lighter in a week like this than in a typical trading week. And it's heavily in favor of selle... Read the Full Story |
|
Medical | |
Heading into the New Year, many folks might be looking to add some new stocks to their portfolio. Of course, healthcare stocks are always worth considering, as the industry is always a buzz, and these three stocks are certainly ones to watch as 2023 begins.
Slow and Steady is the Name of the Game... Read the Full Story |
|
Consumer Discretionary | |
The outlook for 2023 is very cloudy, as seen in the S&P 500 price action. The outlook for all stocks is not the same, however, and the analysts are rewarding those with proven performance and the ability to grow margins in the face of rising inflation.
Today's list includes Biogen (NASDAQ: BI... Read the Full Story |
|
Retail/Wholesale | |
If you are wondering if Dick's Sporting Goods (NYSE: DKS) can score another win in Q4, the odds are high that it will. The company has been exhibiting strength on a sequential and YOY basis driven by product shifts, private label offerings and expanding margins that have the guidance edging higher... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
